Abstract
Discrete-time Markov cohort-state transition models are now well-established as the preferred choice of analysts across application areas including health technology assessment. This preference arises out of its relative intuition and its capability to strike a fine balance between complex disease pathways, statistical precision, and parsimony although being criticized by a wide variety of stakeholders. Transition probability matrices (TPMs) are the “heart and soul” of such models responsible for estimating patient dispositions. However, estimating such TPMs comes with its own set of challenges. In some situations, the transition data may be censored such that the health state of a patient is unknown for multiple time steps before the next observation or data immaturity especially in rare diseases. Craig and Sendi proposed the expectation-maximization (EM) algorithm using uniform weights as a solution for unequal estimation intervals for partially observed data. However, this typically comes at the cost of increased within-state output variations with no optimization technique available in the literature.
The objective of this paper is to explore an optimized weighted version of the original EM algorithm, that aims to estimate the set of weights which minimizes the uncertainty of the estimated TPM against a target objective function. The weighting reduces the uncertainty of the estimate by considering the difference in temporal sparsity of the data when there are missing time steps. Further, we demonstrate the applicability of this weighting method using a fictitious cost-effectiveness model with our approach, showing a fine but definitive change over the original approach.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Data availability statement: The simulated data and R codes are available unrestricted to all readers at our GitHub repository: https://github.com/MarcBollee/EMforMarkov
Funding statement: There was no funding for this project
Conflict of Interest Disclosure: The authors report no conflicts of interest since this a methodological work
Ethics approval: Not applicable
Patient consent statement: Not applicable
Permission to reproduce material from other sources: Not applicable
Clinical trial registration: Not applicable
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.